NTLA

Intellia Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 5/10
  • Value↓ 0/10
Intellia Therapeutics sales and earnings growth
NTLA Growth
Neutral
  • Revenue Y/Y↑ 45.04%
  • EPS Y/Y↑ 32.38%
  • FCF Y/Y↓ 4.60%
Intellia Therapeutics gross and profit margin trends
NTLA Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -597.00%
  • ROIC 5Y↓ -48.34%
Intellia Therapeutics net debt vs free cash flow
NTLA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Intellia Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks